A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
ConditionPsoriasis
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorHansoh BioMedical R&D Company
About this trial
This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.
Eligibility criteria
Qualifiers
Male or female subjects aged 18 years and older
Diagnosis of plaque psoriasis for at least 6 months
Eligible for phototherapy or systemic therapy
Plaque covering ≥ 10% of BSA
Disqualifiers
Diagnosis of non-plaque psoriasis or drug-induced psoriasis
Recent history of infection, history or risk of serious infection
Any major illness or evidence of unstable condition of major organ systems including psychiatric disease
Any condition possibly affecting the PK process of the study drug
Trial design
Treatments tested in this trial
- HS-10374 6mg tablets
- HS-10374-matched placebo tablets
Treatment groups
375 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov